Current Report Filing (8-k)
June 23 2020 - 09:00AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington,
D.C. 20549 FORM 8-K
CURRENT REPORT
Pursuant to Section
13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported): June 23, 2020
GENEREX BIOTECHNOLOGY
CORPORATION
(Exact of registrant
as specified in its charter)
DELAWARE
|
000-29169
|
98-0178636
|
State or other jurisdiction of incorporation
|
Commission File Number
|
IRS Employer Identification No.
|
10102 USA Today
Way, Miramar, Florida 33025
(Address of principal executive offices) (Zip Code)
(416) 364-2551
(Registrant’s
telephone number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13 (a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
N/A
|
N/A
|
N/A
|
Item 8.01 Other Events.
On April 15, 2020, Generex Biotechnology Corporation (“Generex”)
received a letter of support from DiGiovanna Institute for Medical Education & Research, regarding Generex’s efforts
to develop Generex’s li-Key-SARS-CoV-2 peptide vaccine with the goal to begin mass vaccination in the Fall of 2020. A copy
of the letter of support is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
About DiGiovanna Institute
The DiGiovanna Institute for Medical Education & Research was established
in 1990. Dr. Michael J. DiGiovanna D.O., CPI incorporated the Institute as part of the DiGiovanna Family Health and Wellness Center
in order to bring patients of the Center as well as members of the community the latest medical advances in a wide variety of
indications. Dr. DiGiovanna has received his advanced certification as a Certified Principal Investigator from the Association
of Clinical Research Professionals and the Academy of Physicians in Clinical Research.
Dr. DiGiovanna has participated in over 350 clinical
investigations and worked with almost every major pharmaceutical company in the world, such as Pfizer, AstraZeneca, Boehringer
Ingelheim, GlaxoSmithKline, Abbvie, Sanofi, Novo Nordisk, Amgen, Genentech, Roche, Bristol Meyers Squibb, and many others, as
well as many smaller pharmaceutical companies.
Forward-Looking Statements
Statements in this report may contain certain forward-looking
statements. All statements included concerning activities, events or developments that the Generex expects, believes or anticipates
will or may occur in the future are forward-looking statements. Actual results could differ materially from the results discussed
in the forward-looking statements. Forward-looking statements are based on current expectations and projections about future events
and involve known and unknown risks, uncertainties and other factors that may cause actual results and performance to be materially
different from any future results or performance expressed or implied by forward-looking statements. Known risks and uncertainties
also include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which
should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results
or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly
any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when
or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase
of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval
cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any “phase” of clinical
trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of
the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act. Additional information
on these and other risks, uncertainties and factors is included in the Company’s Annual Report on Form 10-K, Quarterly Reports
on Form 10-Q, Current Reports on Form 8- K and other documents filed with the SEC.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
|
Description
|
99.1
|
Letter of Support provided by DiGiovanna Institute for Medical Education & Research dated April 15, 2020
|
April
15, 2020
U.S.
Department of Health and Human Services
200
Independence Avenue SW
Washington,
DC 20201
Office
of the Assistant Secretary for Preparedness and Response (ASPR) and Biomedical Advanced Research and Development Authority (BARDA):
It
is our understanding that Generex Biotechnology is working with the HHS, ASPR, BARDA, and other government agencies to develop
the li-Key-SARS-CoV-2 peptide vaccine with the goal to begin mass vaccination in the Fall of 2020. This will require the collection
of convalescent plasma for the screening and selection of peptides to be included in the final vaccine formulation. This formulation
will then be administered as part of an adaptive design protocol in a clinical trial to assess safety and immunogenicity. Concurrently,
a similar clinical trial will be conducted in a special population of healthcare workers. Subsequent special population trials
will be conducted in pediatric, geriatric, and immunocompromised populations.
On
behalf of DiGiovanna Institute for Medical Education & Research, 1061 North Broadway, 2nd Floor. North
Massapequa NY 11758-1853, please accept this letter as notice of our intent to support Generex Biotechnology and BARDA's
efforts to develop the li-Key-SARSCoV-2/COVlD-19 vaccine. Although we cannot commit financial support or in-kind services, we
are eager to provide clinical and laboratory expertise. As resources permit we are willing to assume Principal Investigator
roles, assist in the collection of convalescent plasma, and serve as a research site for the immunogenicity, healthcare
workers, and special population clinical trials. We recognize the urgent need for vaccine development and are committed to
partnering with Generex Biotechnology and BARDA to make it a reality.
Signature
Name:
Michael J. DiGiovanna D.O., CPI
Title:
President
Affiliations:
DiGiovanna Insttitute for Medical Education & Research Contact Info:
Michael
J. DiGiovanna D.o., CPI
President,
DiGiovanna Institute for Medical Education & Research
1061
North Broadway, 2nd Floor
North
Massapequa, NY 11758-1853
SIGNATURE
Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: June 23, 2020
GENEREX BIOTECHNOLOGY CORPORATION
/s/Joseph Moscato
By: Joseph Moscato, CEO, President
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Mar 2023 to Mar 2024